CervoMed (CRVO) Research & Development (2022 - 2025)
CervoMed (CRVO) has disclosed Research & Development for 5 consecutive years, with $5.8 million as the latest value for Q4 2025.
- Quarterly Research & Development fell 17.73% to $5.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $21.8 million through Dec 2025, up 16.06% year-over-year, with the annual reading at $21.8 million for FY2025, 16.06% up from the prior year.
- Research & Development hit $5.8 million in Q4 2025 for CervoMed, down from $6.0 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $7.1 million in Q4 2024 to a low of $330543.0 in Q3 2022.
- Historically, Research & Development has averaged $3.4 million across 4 years, with a median of $2.8 million in 2023.
- Biggest YoY gain for Research & Development was 650.06% in 2023; the steepest drop was 24.43% in 2023.
- Year by year, Research & Development stood at $380685.0 in 2022, then soared by 650.06% to $2.9 million in 2023, then skyrocketed by 148.19% to $7.1 million in 2024, then decreased by 17.73% to $5.8 million in 2025.
- Business Quant data shows Research & Development for CRVO at $5.8 million in Q4 2025, $6.0 million in Q3 2025, and $5.1 million in Q2 2025.